The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Blood. 2016 Sep 15;128(11):1525-8. doi: 10.1182/blood-2016-02-699439. Epub 2016 Jul 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Arsenic / pharmacokinetics*
  • Arsenic / toxicity
  • Arsenic Trioxide
  • Arsenicals / adverse effects*
  • Arsenicals / pharmacokinetics
  • Arsenicals / therapeutic use
  • Case-Control Studies
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Drug-Related Side Effects and Adverse Reactions / metabolism
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / epidemiology*
  • Leukemia, Promyelocytic, Acute / metabolism
  • Leukemia, Promyelocytic, Acute / mortality
  • Male
  • Oxides / adverse effects*
  • Oxides / pharmacokinetics
  • Oxides / therapeutic use
  • Quality of Life
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Arsenic
  • Arsenic Trioxide